Someone who love kidneys and physiology😷| He, him, his.
Minneapolis, MN
- Tweets 470
- Following 314
- Followers 433
- Likes 3,419
Thank you @SabineKaram6 and the organizing committee for the invitation to talk about Renal Amyloidosis at the inaugural amyloid symposium at UMN. Love these fibrils :) @UMNkidney @onconephsociety
1
14
548
Goad to attend a great talk and discussion about AI and medical education in nephrology by Dr. Mark Rosenberg @UMNkidney @umnmedschool
4
273
New (for kidney) kid in the block! Crovalimab (approved for PNH) shown to have great efficacy and safety from Commute-a; ~60% have complete TMA response AND nearly 100% coming off of dialysis! Presented by @DrBradleyDixon **Slide from Dr. Palma session
5
259
Humble to present our work about comprehensive renal hematological treatment and outcomes of CLL and renal pathology and our proposed concept of CLL of renal significance @LadanZand @Justaglomerular #ASN2026 #kidneyweek2026 @onconephsociety
2
3
25
613
Great talk by @rc_oncneph about how to manage PGNMID! Excited for his upcoming work. #ASN2026 #kidneyweek2026 @onconephsociety
1
1
5
340
Is MGMID an outdated term? Perhaps, SAP (with proper IF technique) would be reasonable one?! A great talk by @Tiff_Caza for this MGRS mimicker. #kidneyweek2026 #ASN
1
3
8
392
Thank you ASN for the great opportunity to moderate a session dear to my heart: TMA. Thanks my co-moderator @nymurakami and a panel of wonderful speakers as well as the esteemed audience! #kidneyweek2026 #ASN
1
25
606
Familiar withMGRS? How about CLL of renal significance? Delighted to present our work on this concept at ASN 2026! See you at 4.30-6.00 PM 10/23/26. More details below ⬇️ @LadanZand @onconephsociety
4
16
985
Join us on at 10.30-12.30 on 10/23/26 for the ABC’s in TMA. Lots of updates about TMA from pathology, nomenclature, classifications and treatments 😇@nymurakami @MPAlexanderMD @kdjhaveri @JohnSperati @Nester1Carla
1
1
12
410
Glad to be part of aHUS foundation conference this year along with @DrBradleyDixon appreciate enthusiasm and great questions from participants! Lots of unmet needs still esp in patient reported outcomes. #ahus #tma #thromboticmicroangiopathy
12
277
Wow! Such a great advancement! When I was in Medical school, I was taught that MM is incurable disease. Thanks to the science! 🧬
We have a cure definition for myeloma.
Requires:
1) Off all therapy and sustained MRD negative for 5 years
2) Negative imaging studies
Presented by @NikhilMunshiMD #IMS26 @Myeloma_Society
Note:
1) We need to see how this definition performs. Relapse rate for patients meeting these cure criteria must ideally be less than 5%. If not, we may have to adjust the criteria.
2) I hope the cure criteria will be the impetus to stop doing trials with endless therapy. You cannot claim cure with continuous therapy. I’m glad the field is mostly aligned on this.
Cure for patients and public in any disease has a deep meaning. Cure means cure. We cannot dilute it.
136
Honored to received an KI-ISN early career research award and excited to attend WCN in Yokohama, Japan this March. Thanks 🙏 @LadanZand @UMNews @ISNkidneycare
𝗞𝗜-𝗜𝗦𝗡 𝗘𝗮𝗿𝗹𝘆 𝗖𝗮𝗿𝗲𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿 𝗔𝘄𝗮𝗿𝗱𝘀:
𝗕𝗮𝘀𝗶𝗰 𝗦𝗰𝗶𝗲𝗻𝗰𝗲:
🇵🇹 Sara Patricia Monteiro-Martins
🇨🇳 Shuai-shuai Xie
𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲:
🇨🇦 Ping Liu
🇺🇸 @basmeomeo
#ISNWCN
3
1
15
1,139
Grateful and honored to be the recipient of KI-ISN early career research award 🥇 2026. See you in Japan 🇯🇵. @LadanZand @UMNews @onconephsociety @ISNkidneycare
10
3
43
1,461
Glad to be part of the USTMA :) @anuja_java and great collaboration.
USTMA Wrapped 2025 🎉🎉🎉
A year powered by collaboration, community & shared purpose!!
We are deeply grateful to our patients, families, clinicians, researchers & advocates who showed what’s possible when a community comes together 🙏🙏
ustma.org
1
1
5
478
Double trouble for membranous nephropathy! Dual-Ag MN have been reported: some co exist with PLA2R1. Nearly 90% of cases have hematuria. Further questions remain: how do these patients differ clinically in terms of clinical characteristics, severity or outcomes? @ASNKidney
1
403
Key take away from Dr. Nasr’ s talk about Cryo GN (one of my fav MGRS).
- Type 2 Cryo is the most common type, HCV being the most common.
- Non-HCV type 2 cryo, still has sizable association with lymphoproliferative d/o>> so attempt to rule this out is suggested ✅🩸 #KidneyWk
3
13
785
Another positive Phase 3 trial of Hit 1 targeted therapy. Awaiting to hear the FDA decision about drug approval by this December so stay tuned. #KidneyWk #IgAN
Presented at #KidneyWk:
In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. Full VISIONARY phase 3 trial results: nej.md/493Xtza
@ASNKidney
ALT A line plot of the least-squares geometric mean change in spot UPCR from baseline
3
311
Great talk by Dr. Falk re: Longterm remission of therapy (LTROT) in ANCA asso GN. Ultimate goal that we should aim for.
-1/3 of ANCA pt achieved this
-risk of relapse decreases with time(10-15% first 1-2 years, 1-2%/yr post 2 y). #KidneyWk
4
7
358
